X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A designed to reduce the dimerization of vitamin A without disrupting vision. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate
Therapeutic Area: Genetic Disease Product Name: ALK-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A designed to reduce the dimerization of vitamin A without disrupting vision. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate
Therapeutic Area: Genetic Disease Product Name: ALK-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The financing will support the registration and launch of ALK-001 (gildeuretinol), a novel, specifically deuterated form of vitamin A and a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness.
Lead Product(s): Gildeuretinol
Therapeutic Area: Genetic Disease Product Name: ALK-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
